- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program | 1 | Investing.com | ||
| 18.12.25 | Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study | 2 | Investing.com | ||
| 18.12.25 | Maze Therapeutics: Leerink Partners hebt Kursziel vor wichtigen Studiendaten auf 50 US-Dollar an | 10 | Investing.com Deutsch | ||
| 04.12.25 | H.C. Wainwright hebt Kursziel für Maze Therapeutics auf 60 US-Dollar an | 9 | Investing.com Deutsch | ||
| 04.12.25 | Maze Therapeutics stock rating initiated at Overweight by Wells Fargo | 4 | Investing.com | ||
| 13.11.25 | Raymond James startet Coverage für Maze Therapeutics mit "Outperform" | 7 | Investing.com Deutsch | ||
| 13.11.25 | Raymond James initiates Maze Therapeutics stock with Outperform rating | 3 | Investing.com | ||
| 06.11.25 | Maze Therapeutics, Inc.: Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | 120 | GlobeNewswire (Europe) | First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected... ► Artikel lesen | |
| 06.11.25 | Maze Therapeutics to present data on kidney disease therapies at ASN meeting | 9 | Investing.com | ||
| 17.10.25 | Maze Therapeutics files to sell 9.23M shares of common stock for holders | 2 | Seeking Alpha | ||
| 17.10.25 | Maze Therapeutics, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 06.10.25 | Maze Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.10.25 | Maze Therapeutics appoints Hervé Hoppenot as board chairman | 10 | Investing.com | ||
| 06.10.25 | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors | 202 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | |
| 03.10.25 | Maze Therapeutics stock rating reiterated at Buy by H.C. Wainwright | 1 | Investing.com | ||
| 03.10.25 | Maze Therapeutics: H.C. Wainwright bestätigt "Buy"-Rating und sieht deutliches Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 19.09.25 | Maze Therapeutics, Inc. (MAZE): A Bull Case Theory | 18 | Insider Monkey | ||
| 15.09.25 | Maze Therapeutics stock price target raised to $34 at Guggenheim on promising PKU data | 3 | Investing.com | ||
| 15.09.25 | Maze Therapeutics: Guggenheim erhöht Kursziel nach vielversprechenden PKU-Studiendaten deutlich auf 34 $ | 1 | Investing.com Deutsch | ||
| 14.09.25 | Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M | 4 | MedCity News |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABIVAX | 100,60 | 0,00 % | EQS-News: ABIVAX: Abivax Provides 2026 Corporate Outlook | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Provides 2026 Corporate Outlook
07.01.2026 / 22:05 CET/CEST
The issuer is solely responsible for the content of... ► Artikel lesen | |
| CYTOKINETICS | 54,00 | -0,92 % | Jefferies raises Cytokinetics stock price target to $90 on ACACIA study | ||
| CYTOMX THERAPEUTICS | 3,774 | +2,83 % | Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) | ||
| UNIQURE | 22,050 | +10,89 % | uniQure Inc.: uniQure Announces Type A Meeting Scheduled with FDA | LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a Type A meeting... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | TENAX THERAPEUTICS, INC. - 8-K, Current Report | ||
| AMYLYX PHARMACEUTICALS | 12,180 | +2,92 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| NURIX THERAPEUTICS | 19,290 | +3,46 % | What 18 Analyst Ratings Have To Say About Nurix Therapeutics | ||
| CELCUITY | 90,00 | 0,00 % | Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? | ||
| APOGEE THERAPEUTICS | 77,70 | +0,28 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| TREVI THERAPEUTICS | 11,235 | +0,18 % | Trevi Therapeutics schedules FDA meeting for chronic cough program | ||
| PEPGEN | 6,460 | -4,15 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen |
MAZE THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 40,400 Euro und damit +3,72 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAZE THERAPEUTICS INC finden Sie auf Wallstreet Online.